3044-06-2

Usage

Uses

Used in Organic Synthesis:
(1-Ethoxyethylidene)propanedioic acid diethyl ester is used as a reagent in organic synthesis for its ability to participate in various chemical reactions, facilitating the creation of a wide array of compounds.
Used in Pharmaceutical Production:
In the pharmaceutical industry, (1-Ethoxyethylidene)propanedioic acid diethyl ester is used as a precursor for the synthesis of various drugs, contributing to the development of new medicinal compounds.
Used in Fragrance Industry:
This ester is employed as a solvent in the fragrance industry, where it helps in the extraction and formulation of scent compounds, enhancing the performance and longevity of fragrances.
Used in Specialty Chemicals:
(1-Ethoxyethylidene)propanedioic acid diethyl ester is used as a solvent in the production of specialty chemicals, which are often required for specific applications in various industries such as coatings, adhesives, and plastics.
Safety Note:
It is crucial to handle (1-Ethoxyethylidene)propanedioic acid diethyl ester with care due to its potential harmful effects if inhaled, ingested, or in contact with skin. Proper safety measures should be taken during its use to minimize health risks.

InChI:InChI=1/C11H18O5/c1-5-14-8(4)9(10(12)15-6-2)11(13)16-7-3/h5-7H2,1-4H3

Upstream product

• 854838-42-9 (1-ethoxy-vinyl)-malonic acid diethyl ester 
• 141-52-6 sodium ethanolate 
• 108-24-7 acetic anhydride 
• 78-39-7 Triethyl orthoacetate 
• 105-53-3 diethyl malonate 
• 2678-54-8 ketene diethyl acetal 
• 74-96-4 ethyl bromide 
• 75-36-5 acetyl chloride 
• 570-08-1 diethyl acetylmalonate 
• 64-67-5 diethyl sulfate 

Downstream Products

• 873963-62-3 (1-ethoxy-vinyl)-allyl-malonic acid diethyl ester 
• 570-08-1 diethyl acetylmalonate 
• 146037-86-7 3-methyl-5-oxo-2,5-dihydro-isoxazole-4-carboxylic acid ethyl ester 
• 41095-07-2 4-chloro-1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester 
• 1374869-11-0 diethyl 2-(1-(3-bromophenylamino)ethylidene)malonate 
• 1228657-25-7 diethyl 2-(1-(5-methylisoxazol-3-ylamino)ethylidene)malonate 
• 66941-63-7 5-(1-ethoxy-vinyl)-5-allyl-barbituric acid 
• 66941-28-4 5-(1-ethoxy-vinyl)-5-ethyl-barbituric acid 
• 66941-21-7 5-(1-ethoxy-ethyl)-5-ethyl-barbituric acid 
• 87948-87-6 5-methyl-1-(2-pyridyl)-7-oxo-1H,7H-pyrazolo<1,5-a>pyrimidine-6-N-(2-pyridyl)carboxamide 
• 50593-70-9 4-chloro-2-methylquinoline-3-carboxylic acid ethyl ester 
• 73987-39-0 ethyl 2-methyl-4-hydroxy-3-quinoline-carboxylate 

Relevant academic research and scientific papers

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidases SpsB and/or LepB, an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Cascade Knoevenagel and aza-Wittig reactions for the synthesis of substituted quinolines and quinolin-4-ols

A [4 + 2] annulation involving cascade Knoevenagel, aza-Wittig and dehydrofluorination reactions is developed for the synthesis of substituted quinolin-4-ols including analogs bearing CF2H, CF3, and C2F5 groups. This simple and highly efficient method is also applicable for the synthesis of substituted quinolines. A number of reported biologically active compounds can be readily prepared by this one-pot synthesis. Green chemistry metrics analysis of the new reaction processes provided favorable results.

Hetero-aromatic compound and its use in medicine

The invention provides a hetero-aromatic compound or a stereisomer, geometric isomer, tautomer, despinner, nitrogen oxide, hydrate, solvate, metabolite, metabolism precursor and pharmaceutically acceptable salt or prodrug thereof, which is used for treating proliferative diseases. The invention also discloses a pharmaceutical composition containing the compound and an application of the compound or pharmaceutical composition thereof in preparation of a medicine for treating proliferative diseases.

Preparation method and use of 2-phenyl-1,6-dihydropyrimidine-5-carboxylic acid derivative

The invention belongs to the technical field of medicines, and relates to a preparation method and a use of a 2-phenyl-1,6-dihydropyrimidine-5-carboxylic acid derivative. The invention provides the 2-phenyl-1,6-dihydropyrimidine-5-carboxylic acid derivative represented by general formula I, or a pharmaceutically acceptable salt, an isomer, a polymorph and a medicinal solvate thereof, and further provides an intermediate for preparing the 2-phenyl-1,6-dihydropyrimidine-5-carboxylic acid derivative or the pharmaceutically acceptable salt thereof. The structure of the intermediate is representedby general formula II, III or IV; and in the formulas, R, R and R are as defined in claims and the description.

CHEMICAL COMPOUNDS

The invention is directed to substituted quinoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R, R1, R2, R3 and R4 are defined herein. The compounds of the invention are inhibitors of lactate dehydrogenase A and can be useful in the treatment of cancer and diseases associated with tumor cell metabolism, such as cancer, and more specifically cancers of the breast, colon, prostate and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting lactate dehydrogenase A activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Synthesis and evaluation of novel pyrimidine-based dual EGFR/Her-2 inhibitors

A structure-activity relationship study of 4-anilinopyrimidines for dual EGFR/Her-2 inhibitor has resulted in the identification of 4-anilino-5-alkenyl or 5-alkynyl-6-methylpyrimidine derivatives that have exhibited effective inhibitory activity against both enzymes. The presence of 5-alkenyl or 5-alkynyl moiety bearing terminal hydrophilic group played important role for inhibition of these enzymes. Selected compounds in the series demonstrated some activity against Her-2 dependent cell line (BT474).

NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES

[Purpose] The present invention provides compounds useful as agents for the prevention or treatment of a sex hormone-dependent disease or the like. [Solution] The present invention provides nitrogen-containing fused ring derivatives represented by the following general formula (I) which has a GnRH antagonistic activity, prodrugs, salts, pharmaceutical compositions containing the same, medicinal uses thereof and the like. In the formula (I), rings A and B are independently aryl or heteroaryl; RA and RB are independently halogen, cyano, alkyl, alkylsulfonyl, -OW1, -SW1, -COW2, -NW3W4, -SO2NW3W4, aryl, etc.; RC is H or alkyl; E is oxygen atom, etc.; U is single bond or alkylene; and X is Y, -CO-Y, -SO2-Y -S-(alkylene)-Y, -O-(alkylene)-Y, -SO2-(alkylene)-Y, etc.; Y is Z or amino, etc.; and Z is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.

Structure-activity relationship of quinoline derivatives as potent and selective α2c-adrenoceptor antagonists

Starting from two acridine compounds identified in a high-throughput screening campaign (1 and 2, Table 1), a series of 4-aminoquinolines was synthesized and tested for their properties on the human α2- adrenoceptor subtypes (α2A, α2B, and α2C). A number of compounds with good antagonist potencies against the α2C-adrenoceptor and excellent subtype selectivities over the other two subtypes were discovered. For example, (R)-{4-[4-(3,4-dimethylpiperazin-1-yl)phenylamino]quinolin-3-yl}methanol 6j had an antagonist potency of 8.5 nM against, and a subtype selectivity of more than 200-fold for, the α2c-adrenoceptor. Investigation of the structure-activity relationship identified a number of structural features, the most critical of which was an absolute need for a substituent in the 3-position of the quinoline ring. The 3-position on the piperazine ring was also found to play an appreciable role, as substitutions in that position exerted a significant and stereospecific beneficial effect on the α2C- adrenoceptor affinity and potency. Replacing the piperazine ring proved difficult, with 1,4-diazepanes representing the only viable alternative.

Process for the preparation of alkoxyalkylidenemalonic acid esters

A process for the preparation of alkoxyalkylidenemalonic acid esters. The reaction is catalyzed by easily separable, insoluble aluminum silicates.